The Characteristics and outcomes of patients with malignant pheochromocytoma and paraganglioma: Single-Center Experience
Introduction: Metastatic pheochromocytoma (PCC) and paraganglioma (PGL) [PPGL] are rare neuroendocrine malignancies characterized by the presence of metastasis in nonchromaffin tissue. However, the data for clinical, histological, or biochemical predictors of metastatic behavior is scarce. So, we aimed to present the clinical features, treatment, and outcomes of our PPGL patients with metastatic behavior. Methods: A total of 38 patients with the diagnosis of PPGLs (n=35 PCCs and n=3 PGLs) were enrolled in the study between 2010 and 2019. The demographics, clinical features, laboratory tests, radiological data, treatments, and outcomes of the patients were analyzed. Results: The mean age was 38.3±15.3 years, and the female to male ratio was 22/16. Underlying etiology was hereditary in 60% of PCCs [multiple endocrine neoplasia (MEN) type 2A in 17 patients; MEN type 2B in 4 patients; and neurofibromatosis in one patient]. The metastatic disease was observed in 5 patients with PPGLs (n=4 of PCCs and n=1 of PGLs). The metastatic cases were sporadic all PPGL patients. The mean maximum size of the primary tumor of metastatic PPGL cases was 4.5±3.2 cm. The sites of metastasis for PCCs were liver, bones, lungs, and lymph nodes in all cases. All metastatic patients underwent surgery. Cytotoxic chemotherapy and 131I- metaiodobenzylguanidine (MIBG) radionuclide therapy were given for all PCCs and external beam radiation for PGL patients. Three of the cases were stable with cytotoxic chemotherapy and 131I-MIBG, but one case exacerbated and died after a total of four cycles of 177Lu therapy. Discussion: In our tertiary referral center, the majority of the patients who were followed with PPGLs have hereditary/genetic etiology. ~10% of our PPGL patients showed malignant features, which was consistent with the literature. Additionally, these patients should be managed in referral centers with a multidisciplinary approach providing chemotherapy and theranostic therapies.
___
[1] Koopman K, Gaal J, de Krijger RR. Pheochromocytomas and Paragangliomas: New Developments with Regard to Classification, Genetics, and Cell of Origin. Cancers 2019;11(8): 1070.[2] Hamidi O, Young WF, Jr., Iniguez-Ariza NM, et al. Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years. J Clin Endocrinol Metab 2017;102(9):3296-305.
[3] Beard CM, Sheps SG, Kurland LT, et al. Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc 1983;58(12):802-4
[4] Neumann HP, Bausch B, McWhinney SR, et al. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002;346(19):1459-66.
[5] Neumann HPH, Young WF, Jr., Eng C. Pheochromocytoma and Paraganglioma. N Engl J Med 2019;381(6):552-65.
[6] Angelousi A, Kassi E, Zografos G, et al. Metastatic pheochromocytoma and paraganglioma. Eur J Clin Invest 2015;45(9):986-97.
[7] Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014;99(6):1915-42.
[8] Hamidi O. Metastatic pheochromocytoma and paraganglioma: recent advances in prognosis and management. Curr Opin Endocrinol Diabetes Obes 2019;26(3):146-54.
[9] Baudin E, Habra MA, Deschamps F, et al. Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma. Eur J Endocrinol 2014;171(3):R111-22.
[10] Plouin PF, Fitzgerald P, Rich T, et al. Metastatic pheochromocytoma and paraganglioma: focus on therapeutics. Horm Metab Res 2012;44(5):390-9.
[11] jimenez C, Rohren E, Habra MA, et al. Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma. Curr Oncol Rep 2013;15(4):356-71.
[12] Ellis RJ, Patel D, Prodanov T, et al. Response after surgical resection of metastatic pheochromocytoma and paraganglioma: can postoperative biochemical remission be predicted? J Am Coll Surg 2013;217(3):489-96.
[13] Vogel J, Atanacio AS, Prodanov T, et al. External beam radiation therapy in treatment of malignant pheochromocytoma and paraganglioma. Front Oncol 2014;4:166.
[14] Ilias I, Divgi C, Pacak K. Current role of metaiodobenzylguanidine in the diagnosis of pheochromocytoma and medullary thyroid cancer. Semin Nucl Med 2011;41(5):364-8.
[15] [Jasim S, Jimenez C. Metastatic pheochromocytoma and paraganglioma: Management of endocrine manifestations, surgery and ablative procedures, and systemic therapies. Best Pract Res Clin Endocrinol Metab 2019:101354.
- ISSN: 2147-9488
- Yayın Aralığı: Yılda 4 Sayı
- Başlangıç: 2012
- Yayıncı: HACETTEPE ÜNİVERSİTESİ
Sayıdaki Diğer Makaleler
Stroke-Like Hemiparesis During Acute Lymphoblastic Leukemia Treatment
İnci Yaman BAJİN, Barış KUŞKONMAZ, Şule ÜNAL, Mualla ÇETİN, Selin ARDALI, Kader KARLI OĞUZ, Fatma GÜMRÜK
Onur KESKİN, Mehmet BEKTAS, Caglar KESKİN, İrfan SOYKAN
Asena Gökçay CANPOLAT, Demet ÇORAPÇIOĞLU
Andro Reginald L. LİCAROS, Johanna Patricia A. CANAL
Aquaporins: A Multidisciplinary Perspective on the Water Channel Proteins
Gokce ALP, Ipek BOSGELMEZ, Yesim OZTAS
Ulas KUMBASAR, EMİNE İPEK ÖZBEK SÖNMEZ, Zeynelabidin OZTURK, Recep Oktay PEKER, Saniye EKİNCİ, Benan BAYRAKCİ, Mustafa YİLMAZ, Riza DOGAN